Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy

This study has been completed.
Sponsor:
Information provided by:
Centocor, Inc.
ClinicalTrials.gov Identifier:
NCT00771667
First received: October 10, 2008
Last updated: March 26, 2013
Last verified: March 2013

October 10, 2008
March 26, 2013
December 2008
May 2010   (final data collection date for primary outcome measure)
Number of Participants With Clinical Response at Week 6 [ Time Frame: Baseline to Week 6 ] [ Designated as safety issue: No ]
As measured by the Crohn's Disease Activity Index (CDAI). CDAI scores range from 0 points (minimal disease activity) to over 600 points (severe disease activity). Clinical response was defined as a reduction from baseline of ≥ 100 points. Participants with a baseline CDAI of ≥ 220 to ≤ 248 were considered to be in clinical response if a CDAI score of < 150 was attained.
To evaluate the clinical response of ustekinumab vs placebo at Week 6 as measured by the reduction from baseline in CDAI.
Complete list of historical versions of study NCT00771667 on ClinicalTrials.gov Archive Site
  • Number of Participants With Clinical Remission at Week 6 [ Time Frame: Baseline to Week 6 ] [ Designated as safety issue: No ]
    As measured by a CDAI score of < 150 points.
  • Number of Participants With Clinical Response at Week 4 [ Time Frame: Baseline to Week 4 ] [ Designated as safety issue: No ]
    As measured by the CDAI. Clinical response was defined as a reduction from baseline of ≥ 100 points. Participants with a baseline CDAI of ≥ 220 to ≤ 248 were considered to be in clinical response if a CDAI score of < 150 was attained.
  • Number of Participants With Clinical Response at Week 8 [ Time Frame: Baseline to Week 8 ] [ Designated as safety issue: No ]
    As measured by the CDAI. Clinical response was defined as a reduction from baseline of ≥ 100 points. Participants with a baseline CDAI of ≥ 220 to ≤ 248 were considered to be in clinical response if a CDAI score of < 150 was attained.
  • Number of Participants With Clinical Remission at Week 8 [ Time Frame: Baseline to Week 8 ] [ Designated as safety issue: No ]
    As measured by a CDAI score of < 150 points.
  • Number of Participants With Clinical Remission at Week 22 (Among Responders From Week 6) [ Time Frame: Baseline to Week 22 ] [ Designated as safety issue: No ]
    As measured by a CDAI score of < 150 points.
  • Number of Participants With Clinical Response at Week 22 (Among Responders From Week 6) [ Time Frame: Baseline to Week 22 ] [ Designated as safety issue: No ]
    As measured by the CDAI. Clinical response was defined as a reduction from baseline of ≥ 100 points. Participants with a baseline CDAI of ≥ 220 to ≤ 248 were considered to be in clinical response if a CDAI score of < 150 was attained.
To evaluate the efficacy of ustikenumab in inducing clinical remission, fistula response and mucosal healing and to obtain data to support the selection of a maintenance dose for continued clinical development.
Not Provided
Not Provided
 
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn's Disease Previously Treated With TNF Antagonist Therapy

A medical research study in adult patients who have moderate to severe Crohn's disease designed to determine whether or not treatment with an experimental drug called ustekinumab (or CNTO1275) is safe or not and to determine if the treatment will reduce the symptoms of Crohn's disease.

In Crohn's disease there is inflammation (changes in body tissue which normally happen during injury or infection) and or ulceration (open sores) in the intestines.This occurs because the immune system (the part of the body that fights off infection) has an abnormal and overactive response against the intestine and bowel tissues of the body. Crohn's disease is usually treated with medications that either directly decrease inflammation or decrease the general activity of the immune system to improve the diarrhea, abdominal pain, and other symptoms of Crohn's Disease. Ustekinumab antibodies (natural substances made by your immune system to stick to and help remove foreign materials in your body that cause diseases) have been created to stick to and block the activity of two of the immune substances thought to cause abnormal inflammation of Crohn's disease. Patients who are eligible and who have received Remicade, Humira, or Cimzia and failed or been intolerant to one of these drugs will be randomized to either active drug (ustekinumab) or placebo. All patients will be randomized (like flipping a coin) at week 0 to be in one of 4 groups. At week 0 the study drug will be given by IV administration and at weeks 8 and 16 by subcutaneous injection. There will be 11 study visits in total and the study will continue until week 36. Blood and stool samples will be collected and studied, questionnaires to check on how you are doing in terms of your disease will be completed, an Electrocardiogram (EKG) obtained, safety evaluations conducted and diary cards distributed to be completed during the entire study. One of 4 groups: Grp 1-placebo, Grp 2-active drug 1mg/kg IV, Grp 3-active drug 3mg/kg IV, Grp 4-active drug 6mg/kg IV. Based on the clinical response status at Week 6, patients from Grps 2, 3 and 4 will be re-randomized at week 8 to receive either placebo or 90 mg SC at both weeks 8 and 16 and patients from Grp 1 will receive placebo at Week 8 and Week 16 or a 270 mg SC injection at Week 8 and 90 mg SC at Week 16.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Crohn's Disease
  • Drug: Placebo (IP)
    Induction phase (Week 0-8) (IP) - Placebo IV group
  • Drug: Ustekinumab 1mg/kg (IP)
    Induction phase (Week 0-8) (IP) - Ustekinumab 1 mg/kg IV group
  • Drug: Ustekinumab 3 mg/kg (IP)
    Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group
  • Drug: Ustekinumab 6 mg/kg (IP)
    Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group
  • Drug: Placebo IV - Responder - Placebo SC (MP)
    Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
  • Drug: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)
    Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 270 mg SC at Week 8 and 90 mg at Week 16
  • Drug: Ustekinumab IV - Responder - Placebo SC (MP)
    Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
  • Drug: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)
    Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
  • Drug: Ustekinumab IV - Nonresponder - Placebo SC (MP)
    Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Placebo SC at Week 8 and Week 16
  • Drug: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
    Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
  • Placebo Comparator: Placebo (IP)
    Intervention: Drug: Placebo (IP)
  • Experimental: Ustekinumab 1mg/kg (IP)
    Intervention: Drug: Ustekinumab 1mg/kg (IP)
  • Experimental: Ustekinumab 3 mg/kg (IP)
    Intervention: Drug: Ustekinumab 3 mg/kg (IP)
  • Experimental: Ustekinumab 6 mg/kg (IP)
    Intervention: Drug: Ustekinumab 6 mg/kg (IP)
  • Placebo Comparator: Placebo IV - Responder - Placebo SC (MP)
    Intervention: Drug: Placebo IV - Responder - Placebo SC (MP)
  • Placebo Comparator: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC
    Intervention: Drug: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)
  • Placebo Comparator: Ustekinumab IV - Responder - Placebo SC (MP)
    Intervention: Drug: Ustekinumab IV - Responder - Placebo SC (MP)
  • Experimental: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)
    Intervention: Drug: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)
  • Placebo Comparator: Ustekinumab IV - Nonresponder - Placebo SC (MP)
    Intervention: Drug: Ustekinumab IV - Nonresponder - Placebo SC (MP)
  • Experimental: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
    Intervention: Drug: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG; CERTIFI Study Group. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012 Oct 18;367(16):1519-28. doi: 10.1056/NEJMoa1203572.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
526
December 2010
May 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Must have Crohn's disease or fistulizing Crohn's disease of at least 3 months duration
  • Must have received Remicade, adalimumab or Cimzia at a dose approved for the treatment of Crohn's disease
  • Must have failed or been intolerant to Remicade, Humira or Cimzia for treatment of Crohn's disease
  • Must be 18 years of age or older
  • Must have active Crohn's disease according to the Crohn's Disease Activity Index (CDAI > =220 and < =450).

Exclusion Criteria:

  • Patients who have had any kind of bowel resection, diversions or placement of a stoma within 6 months
  • Are pregnant, nursing or planning pregnancy (both men and women) while enrolled in the study or within 1 year after receiving study agent
  • Patients who have received Remicade, Humira or Cimzia < =8 weeks before the first administration of study drug
  • Patients with certain complications of Crohn's disease that would make it hard to assess response to study drug
  • Patients with a history of or ongoing chronic or recurrent infectious disease.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Austria,   Belgium,   Canada,   France,   Germany,   Israel,   Netherlands,   New Zealand,   Spain,   United Kingdom
 
NCT00771667
CR015238, C0743T26
Yes
Director, Clinical Research, Janssen R&D US
Centocor, Inc.
Not Provided
Study Director: Centocor, Inc. Clinical Trial Centocor, Inc.
Centocor, Inc.
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP